Aurobindo Pharma Limited has secured a significant regulatory milestone with the US Food & Drug Administration (USFDA) granting final approval for its Dapagliflozin Tablets in 5 mg and 10 mg strengths. This approval positions the company to enter a substantial diabetes medication market as a generic equivalent to AstraZeneca's Farxiga with competitive advantages.

Product Specifications and Market Position

The approved Dapagliflozin Tablets are bioequivalent and therapeutically equivalent to the reference listed drug Farxiga Tablets, manufactured by AstraZeneca AB. The products will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of the company, with immediate market launch planned.

Market Exclusivity and Competitive Advantage

Aurobindo Pharma has secured a notable competitive position by being among the first ANDA applicants to submit a substantially complete application with paragraph IV certification for Dapagliflozin Tablets. This early filing grants the company eligibility for 180 days of shared generic drug exclusivity, providing a significant market advantage during the initial launch period.

The approved product addresses a substantial market opportunity, with IQVIA MAT data indicating an estimated market size of US$ 10.2 billion for the diabetes treatment segment.

Regulatory Portfolio Expansion

With this latest approval, Aurobindo Pharma's USFDA portfolio has expanded to 579 total ANDA approvals. The portfolio breakdown includes:

Therapeutic Application

Dapagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. This therapeutic application addresses a significant healthcare need in the growing diabetes treatment market.

Company Overview

Aurobindo Pharma Limited operates as an integrated global pharmaceutical company headquartered in Hyderabad, India. The company maintains an extensive manufacturing network with over 30 manufacturing and packaging facilities approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA. The company's operations span over 150 countries globally, with a robust product portfolio covering seven major therapeutic areas: CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics, and Anti-Allergic medications.

Aurobindo pharma Limited has secured a significant regulatory milestone with the US Food & Drug Administration (USFDA) granting final approval for its generic diabetes medication. The approval, announced on April 07, 2026, covers Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets in multiple strengths, positioning the company to capture a substantial share of the US diabetes treatment market.

Regulatory Approval Details

The USFDA has approved four different strengths of the diabetes medication, demonstrating the comprehensive nature of Aurobindo Pharma's application. The approved formulations are bioequivalent and therapeutically equivalent to AstraZeneca AB's reference listed drug, Xigduo XR Tablets.

Market Opportunity and Exclusivity Benefits

The approved product represents a significant commercial opportunity for Aurobindo Pharma, with substantial market potential in the competitive US pharmaceutical landscape. The company's strategic positioning as an early applicant has secured valuable market advantages.

As one of the first ANDA applicants to submit a substantially complete application with paragraph IV certification, Aurobindo Pharma has earned the right to 180 days of shared generic drug exclusivity. This exclusivity period provides a competitive advantage by limiting the number of generic competitors in the initial launch phase.

Manufacturing and Portfolio Expansion

The products will be manufactured at Unit-IV of APL Healthcare Limited, a wholly owned subsidiary of Aurobindo Pharma. This approval adds to the company's extensive portfolio of USFDA-approved products, reinforcing its position in the US generics market.

As of March 31, 2026, Aurobindo Pharma holds a total of 579 ANDA approvals from the USFDA, comprising 554 final approvals and 25 tentative approvals. This latest approval strengthens the company's presence in the anti-diabetic therapeutic segment.

Therapeutic Application

Dapagliflozin and Metformin Hydrochloride Extended-Release Tablets are indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type-2 diabetes mellitus. The medication is prescribed when treatment with both dapagliflozin and metformin is clinically appropriate, addressing the growing need for combination therapies in diabetes management.

The immediate launch of these products positions Aurobindo Pharma to serve the substantial US market for type-2 diabetes treatments, leveraging both the market opportunity and the temporary competitive advantage provided by the exclusivity period.